Where mantle cell lymphoma treatment is heading
Mantle cell lymphoma · Updated Nov 14, 2026
About 4,000 people in the US are diagnosed with mantle cell lymphoma each year, mostly men in their 60s and 70s. It used to mean intensive chemotherapy and, for younger people, a stem-cell transplant. BTK inhibitor pills have changed that: they now improve survival when added to first treatment, can replace chemotherapy for older adults, and let many younger people skip transplant.
- 202studies open or running
- 12phase 3 trials
- 345papers published this year
- 32NIH-funded projects
-
Now
Nov 2026
Ibrutinib can replace a stem-cell transplantHappened 90% alive at 4 years
In TRIANGLE, 4-year survival was 90% with ibrutinib and no transplant vs 81% with standard transplant.
90%: alive at 4 years with ibrutinib and no transplant, vs 81% with standard transplant.
Chemotherapy-free first treatment for older adultsHappened 0.69 hazard ratio
Ibrutinib-rituximab cut the risk of progression or death by 31% compared with chemo-immunotherapy.
0.69: hazard ratio for progression or death vs chemo-immunotherapy.
A BTK pill added to first treatmentHappened 66.4 mo median progression-free
Acalabrutinib plus bendamustine-rituximab: median progression-free survival 66.4 vs 49.6 months. FDA approved January 2025.
66.4 mo: median progression-free survival, vs 49.6 months with placebo.
A new pill after BTK inhibitors stop workingHappened
Sonrotoclax, a next-generation BCL-2 inhibitor, won accelerated approval in May 2026.
-
6 months
by May 2027
Zanubrutinib-rituximab heads to regulatorsLikely
MANGROVE beat bendamustine-rituximab as first treatment; filings were planned for late 2026.
-
12 months
by Nov 2027
Who can skip transplant, by blood testLikely
ECOG-ACRIN EA4151 (689 people) tests skipping transplant in people with no detectable residual disease; due January 2027.
A bispecific antibody after BTK inhibitorsPossible 78.3% complete responses (early study)
GLOBRYTE compares glofitamab with standard choices for relapsed disease; due August 2027.
78.3%: complete response rate.
A reversible BTK pill vs older onesPossible
BRUIN MCL-321 (500 people) compares pirtobrutinib with ibrutinib, acalabrutinib or zanubrutinib; due November 2027.
-
3 years
by late 2029
Next-generation pill combination at relapsePossible 31.9 mo with ibrutinib-venetoclax
CELESTIAL-RRMCL (300 people) tests sonrotoclax plus zanubrutinib; due August 2028.
31.9 mo: median progression-free survival, vs 22.1 months with ibrutinib alone.
-
5 years
by late 2031
Taking breaks from BTK pillsLong shot
An Alliance trial (421 people) tests whether intermittent zanubrutinib works as well as continuous; long follow-up runs to 2038.
The research paths
BTK inhibitors move to first treatment
90% alive at 4 yearsDetails and 3 trialsHide
BTK pills added to, or replacing, chemotherapy and transplant.
WatchMANGROVE filing; EA4151.
BCL-2 inhibitor combinations
31.9 mo median progression-freeDetails and 1 trialsHide
Venetoclax and now sonrotoclax paired with BTK inhibitors.
WatchCELESTIAL-RRMCL.
After BTK inhibitors
78.3% complete responsesDetails and 2 trialsHide
Reversible BTK inhibitors, bispecific antibodies and CAR T cells for relapsed disease.
WatchGLOBRYTE; BRUIN MCL-321.
Borrowed from other cancers
From Large B-cell lymphoma
Glofitamab
Phase 3
A CD20xCD3 bispecific first approved for large B-cell lymphoma.
From CLL
Venetoclax and sonrotoclax
Approved / Phase 3
BCL-2 inhibitor pills developed first in chronic lymphocytic leukemia.
Open to join now
-
Relapsed
Sonrotoclax plus zanubrutinib
Locations and eligibility → -
Relapsed after BTK inhibitor
Glofitamab
Locations and eligibility → -
Untreated, older adults
Continuous vs intermittent zanubrutinib
Locations and eligibility → -
Untreated
Orelabrutinib plus bendamustine-rituximab
Locations and eligibility →
See every recruiting Mantle cell lymphoma trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
MANGROVE: zanubrutinib-rituximab beats chemo first-line
BeOne topline.
Sonrotoclax accelerated approval
After a BTK inhibitor.
TRIANGLE: transplant not needed with ibrutinib
The Lancet.
Standard treatment today
- Younger, fit (65 or under)Intensive chemo-immunotherapy with ibrutinib; transplant increasingly omitted.
- Older or less fitBendamustine-rituximab with acalabrutinib, or chemotherapy-free ibrutinib-rituximab.
- TP53-mutated (high risk)Clinical trials; BTK inhibitor combinations preferred over chemotherapy.
- RelapsedBTK inhibitor if not used before; pirtobrutinib, sonrotoclax, CAR T-cell therapy or bispecific antibodies after.
How to read this page, and sourcesHow to read this page, and sources
- A small group of people have slow-growing mantle cell lymphoma that can be watched without treatment; the results here apply to people who need treatment.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Mantle cell lymphoma trials recruiting now →